Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira vs Basal-Bolus in Poorly Controlled T2D
NCT03737240Phase 3Completed
- Sponsor
- Emory University
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec, liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Emory University. Started Jan 2019; status: completed.
02
Drugs
insulin degludecliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03737240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737240.